Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of Covid-19 disease

REFERENCES

• Amanat F, Strohmeier S, Meade P, Dambrauskas N, Mühlemann B, Smith DJ, et al. 2021. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biol. 19(12):1–14. doi:10.1371/journal.pbio.3001384
   Web of Science ®Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. 2020. The proximal origin of SARS-CoV-2. Nat Med. 26:450–452. doi:10.1038/s41591-020-0820-9
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Zhang AJ, Yuan S, Poon VK-M, Chan CC-S, Lee AC, et al. 2020. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 71(9):2428–2446. doi:10.1093/cid/ciaa325
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccines Authorized for Emergency Use. FDA 21.01.22 https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#authorized-vaccines.
   Google Scholar
• Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. 2020. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 33:e00028–20. doi:10.1128/CMR.00028-20.
   PubMed Web of Science ®Google Scholar
• Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson I V, Robicsek A. 2021. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. 326(12):1210–1212. doi:10.1001/jama.2021.13443
   PubMed Web of Science ®Google Scholar
• Dinnon KH, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, et al. 2020. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 586:560–566. doi:10.1038/s41586-020-2708-8.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. 2020 Jul 3. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 369(6499):77–81. DOI: 10.1126/science.abc1932. . Epub 2020 May 6. PMID: 32376603; PMCID: PMC7202686.
   PubMed Web of Science ®Google Scholar
• Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, Wang Y, Teng Y, Zhao Z, Cui Y, et al. 2020 Sep 25. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 369(6511):1603–1607. DOI: 10.1126/science.abc4730. . Epub 2020 Jul 30. PMID: 32732280; PMCID: PMC7574913.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 19:409–424. doi:10.1038/s41579-021-00573-0.
   PubMed Web of Science ®Google Scholar
• Jureka A, Silvas J. 2020. Basler C. propagation, inactivation, propagation, inactivation, and safety testing of SARS-CoV-2. Viruses. 12(6):622. doi:10.3390/v12060622
   PubMed Web of Science ®Google Scholar
• Kärber G. 1931. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. Archiv f. experiment. Pathol. u. Pharmakol. 162:480–483. doi:10.1007/BF01863914
   Google Scholar
• Kumar A, Dowling WE, Román RG, et al. 2021. Status report on COVID-19 vaccines development. Curr Infect Dis Rep. 23(6):9. doi:10.1007/s11908-021-00752-3
   PubMed Web of Science ®Google Scholar
• Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V, et al. 2021. Microvascular injury in the brains of patients with COVID-19. N Engl J Med. 384(5):481–483. doi:10.1056/NEJMc2033369. Epub 2020 Dec 30. PMID: 33378608; PMCID: PMC7787217.
   PubMed Web of Science ®Google Scholar
• Lou F, Li M, Pang Z, Jiang L, Guan L, Tian L, Hu J, Fan J, Fan H. 2021. Understanding the secret of SARS-CoV-2 variants of concern/interest and immune escape. Front Immunol. 12:744242. doi:10.3389/fimmu.2021.744242.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. 2020. Genomic characterization and epidemiology of 2020 genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 395:565–574. doi:10.1016/S0140-6736(20)30251-8
   PubMed Web of Science ®Google Scholar
• Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, et al. 2020. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol. 92(10):2096–2104. doi:10.1002/jmv.25986
   PubMed Web of Science ®Google Scholar
• Mohamed NA, Solehan HM, Mohd Rani MD, Ithnin M, Che Isahak CI. 2021. Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: A web-based survey. PLoS ONE. 16(8):e0256110. doi:10.1371/journal.pone.0256110.
   PubMed Web of Science ®Google Scholar
• Morgeaux SP. 1995. Inactivation of DNA by β-propiolactone. Biologicals. 23(3):207–211. doi:10.1006/biol.1995.0034. PMID: 8527119.
   PubMed Web of Science ®Google Scholar
• Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, et al. 2020. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 11:4059. doi:10.1038/s41467-020-17892-0
   PubMed Web of Science ®Google Scholar
• Pavel STI, Yetiskin H, Aydin G, Holyavkin C, Uygut MA, Dursun ZB, et al. 2020. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PLoS One. 15:1–17. doi:10.1371/journal.pone.0238614
   Web of Science ®Google Scholar
• Portuondo DL, Batista-Duharte A, Ferreira LS, de Andrade CR, Quinello C, Téllez-Martínez D, et al. 2017. Comparative efficacy and toxicity of two vaccine candidates against sporothrix schenckii using either montanide™ Pet Gel A or aluminum hydroxide adjuvants in mice. Vaccine. 35(34):4430–4436. doi:10.1016/j.vaccine.2017.05.046
   PubMed Web of Science ®Google Scholar
• Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, et al. 2006. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine. 24(5):652–661. doi:10.1016/j.vaccine.2005.08.055
   PubMed Web of Science ®Google Scholar
• Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. 2020. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 7(6):1012–1023. doi:10.1093/nsr/nwaa036
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. 2020. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2, cell-182. Cell. 182(3):713–721. doi:10.1016/j.cell.2020.06.008
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. 2020. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. JAMA. 324(10):951–960. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Zeiss CJ, Compton S, Veenhuis RT. 2021. Animal models of COVID-19. I. comparative virology and disease pathogenesis. ILAR J. 62(1-2):35–47. doi:10.1093/ilar/ilab007.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang K, Wang T, Deng F, Gong W, Hui X, et al. 2021. SARS-CoV-2 rapidly adapts in aged BALB/c mice and induces typical pneumonia. J Virol. 95(11):e02477-20. doi:10.1128/jvi.02477-20.
   PubMed Web of Science ®Google Scholar